CRCNJ is now enrolling patients in
blüm, a Phase III clinical trial for CM-AT, a potential first-in-class treatment for autism. CM-AT is developed by Curemark
, LLC, a drug research and development company focused on the treatment of neurological diseases.
CM-AT is based on Curemark's recent research that showed enzyme deficiencies in some autistic children result in an inability to digest protein. The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.
CRCNJ is one of over 20 sites across the country conducting the blüm
Phase III clinical trial of CM-AT in autism.
